Retrospective Cohort Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Dec 14, 2021; 27(46): 7995-8009
Published online Dec 14, 2021. doi: 10.3748/wjg.v27.i46.7995
Table 4 Clinical outcomes and treatment in coronavirus disease 2019 patients with and without gastrointestinal symptoms, n (%)

Total
With GI symptoms n = 163
Without GI symptoms n = 438
P value
Outcomes
ICU admission260 (43.55)78 (48.45)182 (41.74)0.143
ARDS206 (34.30)61 (38.12)145 (33.30)0.268
Shock130 (21.60)40 (25.00)90 (20.64)0.254
MOF48 (8.00)15 (9.32)33 (7.59)0.491
ALF7 (1.20)1 (0.62)6 (1.38)0.447
MV185 (30.80)55 (34.80)130 (29.90)0.252
ECMO4 (0.70)1 (0.62)3 (0.69)0.929
CRRT29 (4.80)6 (3.73)23 (5.28)0.610
Death34 (5.70)10 (6.21)24 (5.50)0.741
LOS (d)15 (8-21)15 (10-22)14 (7-21)0.036a
Treatment
Azithromycin538 (90.12)151 (93.80)387 (88.80)0.068
HCQ540 (90.45)150 (93.20)390 (89.40)0.170
Chloroquine38 (6.30)7 (4.35)31 (7.11)0.388
Antibiotics493 (82.6)149 (92.6)344 (78.9)< 0.001a
Steroids248 (41.61)67 (41.60)181 (41.60)0.831
IFN62 (10.30)21 (13.04)41 (9.43)0.368
RBV91 (15.10)31 (19.25)60 (13.80)0.097
Tocilizumab236 (39.50)66 (40.99)170 (38.99)0.657
Lopinavir/ritonavir340 (56.6)96 (59.6)244 (56.0)0.422
Oseltamivir510 (85.43)139 (86.30)371 (85.09)0.702
Darunavir48 (8.0)14 (8.7)34 (7.8)0.782
Treatment groups
Group 1524 (87.2)150 (92.0)374 (85.4)0.039a
Group 2431 (71.7)128 (78.5)303 (69.2)0.025a
Group 3307 (51.1)88 (54.0)219 (50.0)0.409
Group 4181 (30.1)50 (30.7)131 (29.9)0.920
Group 561 (10.1)22 (13.5)39 (8.9)0.128
Group 656 (9.3)20 (12.3)36 (8.2)0.155